Tuesday, June 7, 2016

Critical Outcome Technologies - COT.v

Critical Outcome Technologies - COT.v represents a multi-pronged approach to value creation in the biopharmaceutical space.

In addition to a potential breakthrough treatment for many cancers, COTI has a robust pipeline of compounds, R&D collaborations and other applications of its core technology.

On June 6, 2016 the company released News

"Critical Outcome Technologies Inc. (TSX Venture: COT; OTCQB: COTQF) (“COTI” or the “Company”) announced today the opening on June 3, 2016, of a second treatment site in its Phase 1 clinical trial of COTI‐2 for gynecological cancers. This site, at the Lurie Cancer Center at Northwestern University in Chicago, Illinois will broaden the base of patients who can potentially qualify for the study with the goal of expediting the enrollment of patients into the trial and thus allowing the overall trial to move forward on a timelier basis.